Starpharma Holdings Limited (SPHRY) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Starpharma Holdings Limited (SPHRY) Healthcare & Pipeline Overview

Starpharma Holdings Limited is a biopharmaceutical company specializing in dendrimer technology for pharmaceuticals, life sciences, and antiviral applications. With products like VivaGel and DEP drug delivery platform, Starpharma targets unmet needs in infectious diseases and oncology, operating in a competitive biotechnology landscape.

What Is the Investment Thesis for SPHRY?

Starpharma's investment thesis hinges on the potential of its DEP drug delivery technology and the continued success of VivaGel. The company's Phase II clinical trials for DEP docetaxel, DEP cabazitaxel, and DEP irinotecan represent significant value drivers, with positive results potentially leading to lucrative licensing agreements or further clinical development. The company's gross margin of 60.1% indicates strong pricing power and efficient operations. However, the company's negative P/E ratio of -60.29 and negative profit margin of -22.7% highlight the risks associated with investing in a development-stage biopharmaceutical company. Upcoming clinical trial results and regulatory approvals are key catalysts, while potential setbacks in clinical development and competition from other therapies represent significant risks.

Based on FMP financials and quantitative analysis

SPHRY Key Highlights

Market capitalization of $227M reflects the company's current valuation in the biotechnology sector.

• Gross margin of 60.1% indicates strong potential profitability from commercialized products.
• Beta of 0.57 suggests lower volatility compared to the overall market.
• VivaGel is a key commercial product targeting the bacterial vaginosis market.
• DEP drug delivery technology is in Phase II clinical trials for multiple oncology indications.

Who Are SPHRY's Competitors?

SPHRY is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are SPHRY's Key Strengths?

Proprietary DEP drug delivery technology.

• Commercialized product (VivaGel) generating revenue.
• Strong gross margin.
• Multiple products in clinical development.

What Are SPHRY's Weaknesses?

Negative profit margin.

• Reliance on partnerships for commercialization.
• Limited financial resources compared to larger pharmaceutical companies.
• Dependence on clinical trial outcomes.

What Could Drive SPHRY Stock Higher?

Results from Phase II clinical trials for DEP docetaxel, DEP cabazitaxel, and DEP irinotecan.

• Regulatory submissions and approvals for VivaGel in new markets.
• Expansion of VivaGel sales and marketing efforts.
• Progress in developing new DEP-based products.
• Formation of new partnerships and collaborations.

What Are the Key Risks for SPHRY?

Negative return on equity (-16.0%) — the business is not currently generating profit on shareholder capital.

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Failure of clinical trials for DEP pipeline.
• Competition from other therapies for bacterial vaginosis and cancer.
• Regulatory delays or rejections.
• Dependence on partnerships for commercialization.
• Limited financial resources.

What Are the Growth Opportunities for SPHRY?

• Expansion of VivaGel into new markets and indications represents a significant growth opportunity for Starpharma. The global market for bacterial vaginosis treatment is estimated to be worth hundreds of millions of dollars, and Starpharma is actively seeking to expand the availability of VivaGel through partnerships and regulatory approvals in new territories. This expansion could drive revenue growth and increase the company's profitability.
• Advancement of DEP pipeline represents a key growth driver for Starpharma. The company's DEP docetaxel, DEP cabazitaxel, and DEP irinotecan are all in Phase II clinical trials for the treatment of various cancers. Positive results from these trials could lead to lucrative licensing agreements or further clinical development, potentially generating significant revenue streams for the company. The oncology market is a large and growing market, and Starpharma's DEP technology could provide a competitive advantage.
• Development of new DEP-based products represents a long-term growth opportunity for Starpharma. The company is actively exploring the use of DEP technology in other therapeutic areas, including radiopharmaceuticals and antibody-drug conjugates (ADCs). These new products could expand Starpharma's addressable market and diversify its revenue streams. The development of new DEP-based products is a long-term process, but it could provide significant value for the company in the future.
• Partnerships and collaborations represent a key growth strategy for Starpharma. The company is actively seeking partnerships with other pharmaceutical and biotechnology companies to develop and commercialize its products and technologies. These partnerships can provide access to new markets, funding, and expertise, accelerating the development and commercialization of Starpharma's products. Strategic alliances are crucial for expanding the reach of its technologies.
• Regulatory approvals for DEP products in key markets, such as the United States and Europe, represent a major growth catalyst. Achieving regulatory approval would validate the safety and efficacy of Starpharma's DEP technology and allow the company to commercialize its products in these large and lucrative markets. Regulatory approvals are a lengthy and complex process, but they are essential for the long-term success of Starpharma.

What Threats Does SPHRY Face?

• Clinical trial failures.
• Competition from other therapies.
• Regulatory hurdles.
• Intellectual property challenges.

What Are SPHRY's Competitive Advantages?

• Proprietary dendrimer technology platform (DEP).
• Patent protection for VivaGel and DEP products.
• Established clinical data supporting the efficacy of its products.
• Partnerships with established pharmaceutical companies.

What Does SPHRY Do?

Founded in 1996 and headquartered in Abbotsford, Australia, Starpharma Holdings Limited is a biopharmaceutical company dedicated to the research, development, and commercialization of dendrimer-based products. The company's core technology revolves around dendrimers, which are highly branched molecules used for drug delivery and other applications. Starpharma's lead product, VivaGel, is a non-antibiotic therapy designed for the management and prevention of bacterial vaginosis (BV). VivaGel is available in several markets and represents a key revenue stream for the company. In addition to VivaGel, Starpharma is developing a range of products based on its proprietary DEP (Dendrimer Enhanced Product) drug delivery technology. DEP is designed to improve the efficacy and reduce the toxicity of existing drugs, particularly in the field of oncology. The company's DEP pipeline includes DEP docetaxel, DEP cabazitaxel, and DEP irinotecan, all of which are in Phase II clinical trials for the treatment of various cancers. Starpharma is also exploring the use of DEP technology in other therapeutic areas, including radiopharmaceuticals and antibody-drug conjugates (ADCs). The company operates globally, seeking partnerships and collaborations to expand the reach of its products and technologies.

What Products and Services Does SPHRY Offer?

• Researches and develops dendrimer products for pharmaceutical applications.
• Commercializes VivaGel, a non-antibiotic therapy for bacterial vaginosis.
• Develops VivaGel condom, an antiviral condom.
• Creates VIRALEZE, an antiviral nasal spray.
• Utilizes DEP, a dendrimer drug delivery technology, to improve existing drugs.
• Conducts clinical trials for DEP docetaxel, DEP cabazitaxel, and DEP irinotecan for cancer treatment.
• Develops oncology programs like DEP radiopharmaceuticals and DEP HER-2 ADC.
• Explores DEP applications beyond oncology.

How Does SPHRY Make Money?

• Develops and patents dendrimer-based technologies.
• Out-licenses its technologies and products to pharmaceutical companies.
• Generates revenue from product sales of VivaGel and VIRALEZE.
• Receives milestone payments and royalties from partnered programs.

What Industry Does SPHRY Operate In?

Starpharma operates in the competitive biotechnology industry, which is characterized by high R&D spending, lengthy regulatory approval processes, and significant clinical trial risks. The market for drug delivery technologies is growing, driven by the need to improve the efficacy and safety of existing drugs. Starpharma's DEP technology positions it to capitalize on this trend, particularly in the oncology space. The company faces competition from other biotechnology companies developing novel drug delivery systems and from established pharmaceutical companies with their own proprietary technologies.

Who Are SPHRY's Key Customers?

• Women seeking treatment for bacterial vaginosis.
• Consumers looking for antiviral protection.
• Pharmaceutical companies licensing Starpharma's technologies.
• Patients participating in clinical trials.

Wall Street analysts project Starpharma Holdings Limited revenue of about $16.0M for fiscal 2026, with EPS near $-0.08.

Starpharma Holdings Limited's Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 25.34 places it in the safe zone, indicating low near-term bankruptcy risk.

Return on equity for Starpharma Holdings Limited stands at -16.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -12.3%, showing how much profit it generates from its asset base. Its free cash flow yield is -0.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 5.26 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -1.0%, the inverse of the P/E and a quick read on earnings relative to price.

Starpharma Holdings Limited (SPHRY) Valuation Context

Valued at $227M, SPHRY is classified as a micro-cap stock. Relative to its peer group, SPHRY's quantitative score of 54/100 is roughly in line with the peer average of 50/100.

SPHRY Revenue & Earnings Trend

In Q4 2025, SPHRY generated $10.6M in top-line revenue, marking a sequential increase of 521.3%. The company recorded net income of $1.3M, with diluted EPS of $0.03. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, SPHRY averaged $-0.08 in diluted EPS.

Company Profile

Starpharma Holdings Limited operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Abbotsford, AU. The company is led by CEO Cheryl Maley. SPHRY has traded publicly since 2007.

SPHRY Financials

SPHRY Latest News

No recent news available for SPHRY.

SPHRY Analyst Consensus

SPHRY MoonshotScore

SPHRY Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources